Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Agios Pharmaceuticals (AGIO) EBT: 2011-2024

Historic EBT for Agios Pharmaceuticals (AGIO) over the last 14 years, with Dec 2024 value amounting to $718.0 million.

  • Agios Pharmaceuticals' EBT fell 110.33% to -$103.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$411.9 million, marking a year-over-year decrease of 156.88%. This contributed to the annual value of $718.0 million for FY2024, which is 303.92% up from last year.
  • Agios Pharmaceuticals' EBT amounted to $718.0 million in FY2024, which was up 303.92% from -$352.1 million recorded in FY2023.
  • Agios Pharmaceuticals' EBT's 5-year high stood at $718.0 million during FY2024, with a 5-year trough of -$356.5 million in FY2021.
  • Its 3-year average for EBT is $44.7 million, with a median of -$231.8 million in 2022.
  • Its EBT has fluctuated over the past 5 years, first slumped by 51.89% in 2023, then soared by 303.92% in 2024.
  • Agios Pharmaceuticals' EBT (Yearly) stood at -$329.3 million in 2020, then dropped by 8.26% to -$356.5 million in 2021, then surged by 34.98% to -$231.8 million in 2022, then crashed by 51.89% to -$352.1 million in 2023, then surged by 303.92% to $718.0 million in 2024.